Health
Patients face coverage gaps following FDA approval of pancreatic cancer drug
Regulatory clearance closed compassionate use programs while insurers delay formal coverage, according to STAT.
The short version
- The FDA approved Revolution Medicines' pancreatic cancer drug Rasonque, prompting the immediate closure of its early access program.[STAT]
- Patients awaiting access now face insurance delays that can last weeks or months, despite the drug carrying a monthly list price near $40,000.[STAT]
- Patient advocates report that applicants stuck in the transition must navigate complex formulary exception appeals or emergency assistance.[STAT]
Key facts
- The FDA approved the pancreatic cancer drug Rasonque, which was developed by Revolution Medicines.[STAT]
- Regulatory approval triggers the immediate shutdown of early access programs, while commercial insurance coverage often takes weeks or months to establish.[STAT]
- Rasonque carries a monthly list price of nearly $40,000.[STAT]
- CVS Health stated that an external panel must review the medication for formal formulary addition, leaving patients to use exception processes in the interim.[STAT]
What remains uncertain
- How rapidly commercial insurers will formally integrate the newly approved drug onto active formularies remains subject to individual committee review timelines.[STAT]
Sources
Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.